Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsv
Publication Title
SITC Annual Meeting November 6-10; Houston, TX. 2024: 497
Document Type
Abstract
Publication Date
11-1-2024
Keywords
oregon; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Comments
Thomas J, Selfridge JE, Albany C, Taylor MH, Mehmi I, Kwatra V, Hu-Lieskovan S, Souza Pd, Mangla A, Llorin-Sangalang J, Aysola K, Hamid O